BioCentury
ARTICLE | Company News

Indevus licenses ATLC compound

July 1, 2002 7:00 AM UTC

IDEV received an exclusive worldwide license from Atlantic Technology Ventures (ATLC) to CT-3 anti-inflammatory and analgesic compound. CT-3 is a synthetic derivative of tetrahydrocannabinol (THC) tha...